PortalPublikationenRegional differences in presentation characteristics, use of...

Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry

Standard

Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry. / Pazdernik, Michal; Gramegna, Mario; Bohm, Allan; Trepa, Maria; Vandenbriele, Christophe; De Rosa, Salvatore; Uzokov, Jamol; Aleksic, Milica; Jarakovic, Milana; El Tahlawi, Mohammad; Mostafa, Morsy; Stratinaki, Maria; Araiza-Garaygordobil, Diego; Gubareva, Ekaterina; Duplyakova, Polina; Chacon-Diaz, Manuel; Refaat, Hesham; Guerra, Federico; Cappelletti, Alberto Maria; Berka, Vojtech; Westermann, Dirk; Schrage, Benedikt.

in: BIOMED PAP, Jahrgang 165, Nr. 3, 09.2021, S. 291-297.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pazdernik, M, Gramegna, M, Bohm, A, Trepa, M, Vandenbriele, C, De Rosa, S, Uzokov, J, Aleksic, M, Jarakovic, M, El Tahlawi, M, Mostafa, M, Stratinaki, M, Araiza-Garaygordobil, D, Gubareva, E, Duplyakova, P, Chacon-Diaz, M, Refaat, H, Guerra, F, Cappelletti, AM, Berka, V, Westermann, D & Schrage, B 2021, 'Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry', BIOMED PAP, Jg. 165, Nr. 3, S. 291-297. https://doi.org/10.5507/bp.2021.046

APA

Pazdernik, M., Gramegna, M., Bohm, A., Trepa, M., Vandenbriele, C., De Rosa, S., Uzokov, J., Aleksic, M., Jarakovic, M., El Tahlawi, M., Mostafa, M., Stratinaki, M., Araiza-Garaygordobil, D., Gubareva, E., Duplyakova, P., Chacon-Diaz, M., Refaat, H., Guerra, F., Cappelletti, A. M., ... Schrage, B. (2021). Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry. BIOMED PAP, 165(3), 291-297. https://doi.org/10.5507/bp.2021.046

Vancouver

Pazdernik M, Gramegna M, Bohm A, Trepa M, Vandenbriele C, De Rosa S et al. Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry. BIOMED PAP. 2021 Sep;165(3):291-297. https://doi.org/10.5507/bp.2021.046

Bibtex

@article{da4e6d3df0264cebacec3a7165cad6be,
title = "Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry",
abstract = "BACKGROUND: Concurrent evidence about cardiogenic shock (CS) characteristics, treatment and outcome does not represent a global spectrum of patients and is therefore limited. The aim of this study was to investigate these regional differences.METHODS: To investigate regional differences in presentation characteristics, treatments and outcomes of patients treated with all types of cardiogenic shock (CS) in a single calendar year on a multi-national level. Consecutive patients from 19 tertiary care hospitals in 13 countries with CS who were treated between January 1, 2018 and December 31, 2018 were enrolled in this study.RESULTS: In total, 699 cardiogenic shock patients were included in this study. Of these patients, 440 patients (63%) were treated in European hospitals and 259 (37%) were treated in Non-European hospitals. Female patients (P<0.01) and patients with a previous myocardial infarction (P=0.02) were more likely to present at Non-European hospitals; whereas older patients (P=0.01) and patients with cardiogenic shock due to acute heart failure (P<0.01) were more likely to present at European hospitals. Vasopressor use was more likely in Non-European hospitals (P=0.04), whereas use of mechanical circulatory support (MCS) was more likely in European hospitals (P<0.01). Despite adjustment for relevant confounders, 30-day in-hospital mortality risk was comparably high in CS patients treated in European vs. Non-European hospitals (hazard ratio 1.08, 95% CI 0.84-1.39, P=0.56).CONCLUSION: Despite marked heterogeneity in characteristics and treatment of CS patients, including fewer use of MCS but more frequent use of vasopressors in Non-European hospitals, 30-day in-hospital mortality did not differ between regions.",
keywords = "Female, Heart-Assist Devices, Hospital Mortality, Humans, Registries, Risk Factors, Shock, Cardiogenic/therapy, Time Factors, Treatment Outcome",
author = "Michal Pazdernik and Mario Gramegna and Allan Bohm and Maria Trepa and Christophe Vandenbriele and {De Rosa}, Salvatore and Jamol Uzokov and Milica Aleksic and Milana Jarakovic and {El Tahlawi}, Mohammad and Morsy Mostafa and Maria Stratinaki and Diego Araiza-Garaygordobil and Ekaterina Gubareva and Polina Duplyakova and Manuel Chacon-Diaz and Hesham Refaat and Federico Guerra and Cappelletti, {Alberto Maria} and Vojtech Berka and Dirk Westermann and Benedikt Schrage",
year = "2021",
month = sep,
doi = "10.5507/bp.2021.046",
language = "English",
volume = "165",
pages = "291--297",
journal = "BIOMED PAP",
issn = "1213-8118",
publisher = "Palacky University",
number = "3",

}

RIS

TY - JOUR

T1 - Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry

AU - Pazdernik, Michal

AU - Gramegna, Mario

AU - Bohm, Allan

AU - Trepa, Maria

AU - Vandenbriele, Christophe

AU - De Rosa, Salvatore

AU - Uzokov, Jamol

AU - Aleksic, Milica

AU - Jarakovic, Milana

AU - El Tahlawi, Mohammad

AU - Mostafa, Morsy

AU - Stratinaki, Maria

AU - Araiza-Garaygordobil, Diego

AU - Gubareva, Ekaterina

AU - Duplyakova, Polina

AU - Chacon-Diaz, Manuel

AU - Refaat, Hesham

AU - Guerra, Federico

AU - Cappelletti, Alberto Maria

AU - Berka, Vojtech

AU - Westermann, Dirk

AU - Schrage, Benedikt

PY - 2021/9

Y1 - 2021/9

N2 - BACKGROUND: Concurrent evidence about cardiogenic shock (CS) characteristics, treatment and outcome does not represent a global spectrum of patients and is therefore limited. The aim of this study was to investigate these regional differences.METHODS: To investigate regional differences in presentation characteristics, treatments and outcomes of patients treated with all types of cardiogenic shock (CS) in a single calendar year on a multi-national level. Consecutive patients from 19 tertiary care hospitals in 13 countries with CS who were treated between January 1, 2018 and December 31, 2018 were enrolled in this study.RESULTS: In total, 699 cardiogenic shock patients were included in this study. Of these patients, 440 patients (63%) were treated in European hospitals and 259 (37%) were treated in Non-European hospitals. Female patients (P<0.01) and patients with a previous myocardial infarction (P=0.02) were more likely to present at Non-European hospitals; whereas older patients (P=0.01) and patients with cardiogenic shock due to acute heart failure (P<0.01) were more likely to present at European hospitals. Vasopressor use was more likely in Non-European hospitals (P=0.04), whereas use of mechanical circulatory support (MCS) was more likely in European hospitals (P<0.01). Despite adjustment for relevant confounders, 30-day in-hospital mortality risk was comparably high in CS patients treated in European vs. Non-European hospitals (hazard ratio 1.08, 95% CI 0.84-1.39, P=0.56).CONCLUSION: Despite marked heterogeneity in characteristics and treatment of CS patients, including fewer use of MCS but more frequent use of vasopressors in Non-European hospitals, 30-day in-hospital mortality did not differ between regions.

AB - BACKGROUND: Concurrent evidence about cardiogenic shock (CS) characteristics, treatment and outcome does not represent a global spectrum of patients and is therefore limited. The aim of this study was to investigate these regional differences.METHODS: To investigate regional differences in presentation characteristics, treatments and outcomes of patients treated with all types of cardiogenic shock (CS) in a single calendar year on a multi-national level. Consecutive patients from 19 tertiary care hospitals in 13 countries with CS who were treated between January 1, 2018 and December 31, 2018 were enrolled in this study.RESULTS: In total, 699 cardiogenic shock patients were included in this study. Of these patients, 440 patients (63%) were treated in European hospitals and 259 (37%) were treated in Non-European hospitals. Female patients (P<0.01) and patients with a previous myocardial infarction (P=0.02) were more likely to present at Non-European hospitals; whereas older patients (P=0.01) and patients with cardiogenic shock due to acute heart failure (P<0.01) were more likely to present at European hospitals. Vasopressor use was more likely in Non-European hospitals (P=0.04), whereas use of mechanical circulatory support (MCS) was more likely in European hospitals (P<0.01). Despite adjustment for relevant confounders, 30-day in-hospital mortality risk was comparably high in CS patients treated in European vs. Non-European hospitals (hazard ratio 1.08, 95% CI 0.84-1.39, P=0.56).CONCLUSION: Despite marked heterogeneity in characteristics and treatment of CS patients, including fewer use of MCS but more frequent use of vasopressors in Non-European hospitals, 30-day in-hospital mortality did not differ between regions.

KW - Female

KW - Heart-Assist Devices

KW - Hospital Mortality

KW - Humans

KW - Registries

KW - Risk Factors

KW - Shock, Cardiogenic/therapy

KW - Time Factors

KW - Treatment Outcome

U2 - 10.5507/bp.2021.046

DO - 10.5507/bp.2021.046

M3 - SCORING: Journal article

C2 - 34421120

VL - 165

SP - 291

EP - 297

JO - BIOMED PAP

JF - BIOMED PAP

SN - 1213-8118

IS - 3

ER -